Research into rare diseases has long faced obstacles, from limited patient numbers to the challenge of replicating disease biology in the lab. A new wave of innovation, highlighted in the recent Frontiers in Science magazine collection, is changing the landscape: the use of induced pluripotent stem cell (iPSC)-based model systems is offering scientists powerful new ways to study and eventually treat rare diseases.
iPSCs are adult cells reprogrammed to behave like embryonic stem cells, with the ability to become nearly any cell type in the human body. This technology allows researchers to create patient-specific cell models that carry the exact genetic mutations responsible for different rare diseases. By turning these iPSCs into neurons, heart cells, or muscle cells, scientists can observe how the disease unfolds at a cellular level—something that was previously impossible with traditional animal models or cell lines.
The Frontiers in Science research topic collection brings together cutting-edge studies and reviews that demonstrate the versatility of iPSC-based models. One of the major advantages is the ability to recapitulate disease mechanisms in a controlled environment. For example, iPSC-derived neurons from patients with rare neurodegenerative diseases can be analyzed for abnormal protein aggregation, synaptic dysfunction, or altered signaling pathways. This direct window into disease biology accelerates the identification of new therapeutic targets.
Another important application is drug screening and personalized medicine. Since iPSCs can be generated from individual patients, they enable “disease-in-a-dish” models for high-throughput drug testing. Researchers can screen hundreds or thousands of compounds to see which ones correct cellular defects, paving the way for more tailored treatment strategies. In some cases, these platforms have already helped identify existing drugs that could be repurposed to treat rare diseases.
Despite these advances, the collection also acknowledges key challenges. iPSC models are technically demanding to create and maintain, and faithfully replicating the full complexity of a disease remains difficult. Additionally, not all rare diseases affect cell types that can be easily generated from iPSCs. Nevertheless, continued improvements in gene editing, differentiation protocols, and analytical techniques are steadily overcoming these barriers.
The magazine collection emphasizes collaborative efforts between clinicians, geneticists, and stem cell biologists as crucial to driving the field forward. By sharing standardized protocols, patient-derived cell lines, and big data resources, the rare disease community is building a global foundation for faster progress.
